Thermo Fisher Scientific Inc. (TMO) Carries a Mid-Single Digit Organic Growth Forecast

Core Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) is recognized as one of the top life sciences stocks to buy according to hedge funds, with analysts maintaining positive ratings and price targets [1][3] Financial Performance - The company reported a revenue growth of 3.91% over the past twelve months, achieving total revenue of $44.56 billion [2] - Management provided guidance for organic growth in 2026, forecasting a range of approximately 3–6%, with an initial lean towards the lower end of this range, indicating a cautious but stable outlook [2] Analyst Ratings - Daniel Arias from Stifel Nicolaus maintained a Buy rating on TMO with a price target of $700, highlighting a strong finish to 2025 and a solid Q4 performance [1] - Catherine Schulte from Baird raised the price target from $645 to $653 while maintaining an Outperform rating, reflecting a positive revision of their model following the fourth-quarter announcement [3] Business Segments - Thermo Fisher Scientific Inc. provides high-end life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, serving various markets including academics, biotechnology, government, and pharmaceuticals [4]